论文部分内容阅读
阿霉素(ADM)属于蒽环类抗生素,用它治疗一系列实体瘤(乳腺癌、肺癌、卵巢癌、膀胱癌、甲状腺癌、软组织肉瘤、原发性肝癌等),也用于治疗某些血组织增生病(急性白血病、淋巴肉芽肿瘤)。ADM毒性表现为抑制造血功能(白细胞与淋巴细胞减少),以及脱发、恶心、呕吐、口腔炎,但这些副作用具有可逆性,一旦停药后症状即可消失。但是ADM正如蒽环类中其它抗肿瘤抗生素一样也具有心脏毒性作用,有时引起心肌病和郁血性心功能不全。ADM因治疗许多恶性肿瘤被广泛地应用,所以及早诊断、预防和治疗这类抗生素所引起的心肌中毒是一个迫切问题。文献报道在阿霉素心肌毒性的一些风险因子中,主要风险因子是体内ADM总蓄积
Adriamycin (ADM) is an anthracycline that is used to treat a range of solid tumors (breast, lung, ovarian, bladder, thyroid, soft tissue sarcoma, primary liver, etc.) Blood Hyperplasia (acute leukemia, lymphoid granulomatous tumor). ADM toxicity appears to inhibit hematopoietic function (leukopenia and lymphopenia), as well as hair loss, nausea, vomiting, and stomatitis, but these side effects are reversible and disappear once the drug is discontinued. But ADM, like other antitumor antibiotics in anthracyclines, also has cardiotoxic effects, sometimes causing cardiomyopathy and bloody heart failure. Because ADM is widely used in the treatment of many malignancies, the early diagnosis, prevention and treatment of myocardial toxicity caused by such antibiotics is a pressing issue. Reported in the literature some of the risk factors for myocardial toxicity of doxorubicin, the main risk factor is the total volume of ADM in vivo